Compare Daiichi Sankyo Co., Ltd. with Similar Stocks
Dashboard
1
The company is Net-Debt Free
2
Healthy long term growth as Net Sales has grown by an annual rate of 16.32% and Operating profit at 33.85%
3
Negative results in Mar 26
4
With ROE of 17.81%, it has a attractive valuation with a 3.30 Price to Book Value
5
Majority shareholders : Non Institution
6
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 4,716,933 Million (Large Cap)
19.00
NA
0.00%
-0.14
17.81%
2.76
Revenue and Profits:
Net Sales:
589,586 Million
(Quarterly Results - Mar 2026)
Net Profit:
42,428 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.79%
0%
-11.79%
6 Months
-26.14%
0%
-26.14%
1 Year
-23.14%
0%
-23.14%
2 Years
-55.14%
0%
-55.14%
3 Years
-44.82%
0%
-44.82%
4 Years
-23.45%
0%
-23.45%
5 Years
3.7%
0%
3.7%
Daiichi Sankyo Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.32%
EBIT Growth (5y)
33.85%
EBIT to Interest (avg)
14.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.37
Sales to Capital Employed (avg)
0.98
Tax Ratio
16.91%
Dividend Payout Ratio
38.47%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
15.44%
ROE (avg)
9.72%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
3.30
EV to EBIT
17.29
EV to EBITDA
13.97
EV to Capital Employed
3.67
EV to Sales
2.63
PEG Ratio
0.67
Dividend Yield
NA
ROCE (Latest)
21.25%
ROE (Latest)
17.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 4 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
589,586.00
518,689.00
13.67%
Operating Profit (PBDIT) excl Other Income
15,025.00
100,803.00
-85.09%
Interest
3,568.00
7,078.00
-49.59%
Exceptional Items
0.00
0.00
Consolidate Net Profit
42,428.00
87,153.00
-51.32%
Operating Profit Margin (Excl OI)
-37.50%
159.70%
-19.72%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 13.67% vs 21.07% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -51.32% vs 136.10% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
2,123,045.00
1,886,256.00
12.55%
Operating Profit (PBDIT) excl Other Income
310,351.00
377,392.00
-17.76%
Interest
6,074.00
3,401.00
78.59%
Exceptional Items
-1,587.00
-1,490.00
-6.51%
Consolidate Net Profit
259,874.00
295,756.00
-12.13%
Operating Profit Margin (Excl OI)
102.20%
163.70%
-6.15%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 12.55% vs 17.77% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -12.13% vs 47.13% in Mar 2025
About Daiichi Sankyo Co., Ltd. 
Daiichi Sankyo Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






